BULLFROG AI HOLDINGS, INC. Increase (Decrease) in Accrued Liabilities
BULLFROG AI HOLDINGS, INC. (BFRG) reported Increase (Decrease) in Accrued Liabilities of -$122.36 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-14
- BULLFROG AI HOLDINGS, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $112.81K.
- BULLFROG AI HOLDINGS, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$235.17K, a 175.22% decline year-over-year.
- BULLFROG AI HOLDINGS, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was -$38.51K.
- BULLFROG AI HOLDINGS, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $213.46K, a 13.66% decline year-over-year.
- BULLFROG AI HOLDINGS, INC. increase (decrease) in accrued liabilities for fiscal 2025 was $336.71K, a 371.18% increase from fiscal 2024.
- BULLFROG AI HOLDINGS, INC. increase (decrease) in accrued liabilities for fiscal 2024 was $71.46K.
- BULLFROG AI HOLDINGS, INC. increase (decrease) in accrued liabilities for fiscal 2023 was -$838.43K, a 324.62% decline from fiscal 2022.
- BULLFROG AI HOLDINGS, INC. increase (decrease) in accrued liabilities for fiscal 2022 was $373.27K, a 1263.11% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $112.81K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$122.36K 10-Q · filed 2026-08-14 | -$160.88K derived: sum of 3 quarters · filed 2026-08-14 | $52.59K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$235.17K 10-Q · filed 2026-05-14 | -$273.68K derived: sum of 2 quarters · filed 2026-05-14 | -$60.22K derived: sum of 3 quarters · filed 2026-05-14 | -$211.09K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$38.51K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $174.95K derived: sum of 2 quarters · filed 2026-03-19 | $24.08K derived: sum of 3 quarters · filed 2026-08-14 | $336.71K 10-K · filed 2026-03-19 |
| 2025-09-30 | $213.46K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $62.59K derived: sum of 2 quarters · filed 2026-08-14 | $375.23K 10-Q · filed 2025-11-14 | $11.72K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$150.87K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $161.77K 10-Q · filed 2026-08-14 | -$201.74K derived: sum of 3 quarters · filed 2026-08-14 | $45.48K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $312.64K 10-Q · filed 2026-05-14 | -$50.86K derived: sum of 2 quarters · filed 2026-05-14 | $196.36K derived: sum of 3 quarters · filed 2026-05-14 | $281.96K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$363.50K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$116.28K derived: sum of 2 quarters · filed 2026-03-19 | -$30.68K derived: sum of 3 quarters · filed 2026-03-19 | $71.46K 10-K · filed 2026-03-19 |
| 2024-09-30 | $247.22K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $332.82K derived: sum of 2 quarters · filed 2025-11-14 | $434.96K 10-Q · filed 2025-11-14 | $393.40K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $85.60K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $187.74K 10-Q · filed 2025-08-13 | $146.18K derived: sum of 3 quarters · filed 2025-08-13 | $72.53K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $102.14K 10-Q · filed 2025-05-13 | $60.58K derived: sum of 2 quarters · filed 2025-05-13 | -$13.07K derived: sum of 3 quarters · filed 2025-05-13 | -$128.06K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$41.56K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | -$115.21K derived: sum of 2 quarters · filed 2025-03-14 | -$230.20K derived: sum of 3 quarters · filed 2025-03-14 | -$838.43K 10-K · filed 2025-03-14 |
| 2023-09-30 | -$73.65K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | -$188.64K derived: sum of 2 quarters · filed 2024-11-08 | -$796.87K 10-Q · filed 2024-11-08 | -$833.09K derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | -$114.99K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$723.22K 10-Q · filed 2024-08-07 | -$759.45K derived: sum of 3 quarters · filed 2024-08-07 | -$643.16K derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | -$608.23K 10-Q · filed 2024-05-10 | -$644.46K derived: sum of 2 quarters · filed 2024-05-10 | -$528.17K derived: sum of 3 quarters · filed 2024-05-10 | -$647.59K derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | -$36.23K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $80.06K derived: sum of 2 quarters · filed 2024-03-29 | -$39.36K derived: sum of 3 quarters · filed 2024-03-29 | $373.27K 10-K · filed 2024-03-29 |
| 2022-09-30 | $116.29K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$3.13K derived: sum of 2 quarters · filed 2023-11-14 | $409.50K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | -$119.42K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $293.21K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $412.63K 10-Q · filed 2023-05-24 | |||
| 2021-12-31 | $27.38K 10-K · filed 2023-04-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B |